GlassScriptPhysician profile
Manjunath Balaram
NPI 1790042836
$2,386.42
in general payments reported to CMS, 2019-2025
12 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $1,726 · 2024: $325 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,306 · Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,306.04 |
| Food and Beverage | $893.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,574.38 | 2023 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $179.64 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $126.59 | 2022-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $114.59 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $87.50 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $66.07 | 2022-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $63.68 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $57.93 | 2024 | Trintellix |
| Alkermes, INC. | $53.63 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $22.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.05 | 2024 | Cobenfy |
| Lundbeck LLC | $19.77 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjunath Balaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.